Croatia

Croatia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
1.08 (0.99 - 1.17) 2019 Modelled IHME
1.15 (1.05 - 1.24) 2018 Modelled IHME
1.18 (1.08 - 1.28) 2017 Modelled IHME
1.18 (1.09 - 1.27) 2016 Modelled IHME
1.18 (1.08 - 1.27) 2015 Modelled IHME
1.18 (1.09 - 1.28) 2014 Modelled IHME
1.2 (1.11 - 1.30) 2013 Modelled IHME
1.23 (1.13 - 1.32) 2012 Modelled IHME
1.26 (1.16 - 1.36) 2011 Modelled IHME
1.28 (1.18 - 1.39) 2010 Modelled IHME
1.31 (1.20 - 1.42) 2009 Modelled IHME
1.33 (1.23 - 1.44) 2008 Modelled IHME
1.36 (1.25 - 1.47) 2007 Modelled IHME
1.38 (1.27 - 1.49) 2006 Modelled IHME
1.41 (1.30 - 1.53) 2005 Modelled IHME
1.43 (1.32 - 1.55) 2004 Modelled IHME
1.46 (1.35 - 1.58) 2003 Modelled IHME
1.48 (1.37 - 1.61) 2002 Modelled IHME
1.51 (1.40 - 1.63) 2001 Modelled IHME
1.54 (1.41 - 1.66) 2000 Modelled IHME
1.56 (1.44 - 1.69) 1999 Modelled IHME
1.59 (1.48 - 1.71) 1998 Modelled IHME
1.62 (1.50 - 1.75) 1997 Modelled IHME
1.64 (1.52 - 1.77) 1996 Modelled IHME
1.66 (1.52 - 1.79) 1995 Modelled IHME
1.66 (1.53 - 1.80) 1994 Modelled IHME
1.67 (1.54 - 1.81) 1993 Modelled IHME
1.67 (1.54 - 1.82) 1992 Modelled IHME
1.67 (1.54 - 1.83) 1991 Modelled IHME
1.67 (1.53 - 1.84) 1990 Modelled IHME
0.7 (0.40 - 1.20) 2016 Modelled ECDC
0.8 (0.40 - 1.20) 2011 Survey/reported Vilibic-Cavlek T et al, 2014
2.3 (0.90 - 5) 2010 Survey/reported Burek et al, 2010
0.88 (0.65 - 1.18) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.09 (0.07 - 0.11) 2019 Modelled IHME
0.09 (0.07 - 0.11) 2018 Modelled IHME
0.09 (0.07 - 0.11) 2017 Modelled IHME
0.09 (0.07 - 0.10) 2016 Modelled IHME
0.08 (0.06 - 0.10) 2015 Modelled IHME
0.08 (0.06 - 0.09) 2014 Modelled IHME
0.07 (0.06 - 0.09) 2013 Modelled IHME
0.07 (0.05 - 0.08) 2012 Modelled IHME
0.07 (0.05 - 0.08) 2011 Modelled IHME
0.07 (0.05 - 0.08) 2010 Modelled IHME
0.07 (0.05 - 0.08) 2009 Modelled IHME
0.07 (0.05 - 0.08) 2008 Modelled IHME
0.07 (0.05 - 0.08) 2007 Modelled IHME
0.07 (0.05 - 0.08) 2006 Modelled IHME
0.07 (0.05 - 0.08) 2005 Modelled IHME
0.07 (0.06 - 0.08) 2004 Modelled IHME
0.07 (0.06 - 0.08) 2003 Modelled IHME
0.07 (0.06 - 0.09) 2002 Modelled IHME
0.08 (0.07 - 0.10) 2001 Modelled IHME
0.09 (0.07 - 0.10) 2000 Modelled IHME
0.19 (0.15 - 0.22) 1999 Modelled IHME
0.41 (0.33 - 0.49) 1998 Modelled IHME
0.68 (0.54 - 0.80) 1997 Modelled IHME
0.9 (0.72 - 1.07) 1996 Modelled IHME
0.99 (0.79 - 1.20) 1995 Modelled IHME
0.99 (0.79 - 1.19) 1994 Modelled IHME
1 (0.80 - 1.20) 1993 Modelled IHME
1 (0.79 - 1.20) 1992 Modelled IHME
1 (0.79 - 1.20) 1991 Modelled IHME
1 (0.78 - 1.21) 1990 Modelled IHME
0.11 (0.07 - 0.17) 2015 Modelled WHO
Showing out of
Show more
Men who have sex with men (MSM)
Download
Value (%) Year Type Source
0.56 (0.10 - 2) 2006 Survey/reported Bozicevic I et al, 2009
Prisoners
Download
Value (%) Year Type Source
1.3 (1 - 1.60) 2016 Modelled ECDC

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
20 (14 - 27) 2019 Modelled IHME
20 (14 - 27) 2018 Modelled IHME
20 (14 - 27) 2017 Modelled IHME
20 (14 - 27) 2016 Modelled IHME
20 (14 - 27) 2015 Modelled IHME
20 (14 - 27) 2014 Modelled IHME
20 (14 - 27) 2013 Modelled IHME
20 (14 - 27) 2012 Modelled IHME
20 (14 - 27) 2011 Modelled IHME
20 (14 - 27) 2010 Modelled IHME
20 (14 - 28) 2009 Modelled IHME
21 (15 - 28) 2008 Modelled IHME
21 (15 - 29) 2007 Modelled IHME
22 (16 - 30) 2006 Modelled IHME
22 (16 - 31) 2005 Modelled IHME
22 (16 - 31) 2004 Modelled IHME
22 (16 - 31) 2003 Modelled IHME
22 (16 - 31) 2002 Modelled IHME
22 (16 - 31) 2001 Modelled IHME
22 (16 - 31) 2000 Modelled IHME
23 (16 - 31) 1999 Modelled IHME
23 (16 - 31) 1998 Modelled IHME
23 (16 - 31) 1997 Modelled IHME
23 (16 - 32) 1996 Modelled IHME
23 (16 - 32) 1995 Modelled IHME
23 (16 - 32) 1994 Modelled IHME
23 (16 - 32) 1993 Modelled IHME
23 (16 - 32) 1992 Modelled IHME
23 (16 - 31) 1991 Modelled IHME
23 (16 - 31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
98 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
93 2018 Survey/reported WHO/UNICEF
92 2017 Survey/reported WHO/UNICEF
92 2016 Survey/reported WHO/UNICEF
94 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
97 2010 Survey/reported WHO/UNICEF
97 2009 Survey/reported WHO/UNICEF
97 2008 Survey/reported WHO/UNICEF
94 2007 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
192 2017 Survey/reported EMCDDA, 2019
146 (112 - 179) 2016 Survey/reported Handanagic S et al, 2016
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
54 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.92 (0.75 - 1.13) 2019 Modelled IHME
0.92 (0.75 - 1.12) 2018 Modelled IHME
0.91 (0.74 - 1.11) 2017 Modelled IHME
0.9 (0.73 - 1.09) 2016 Modelled IHME
0.89 (0.73 - 1.08) 2015 Modelled IHME
0.89 (0.73 - 1.08) 2014 Modelled IHME
0.89 (0.73 - 1.08) 2013 Modelled IHME
0.89 (0.73 - 1.08) 2012 Modelled IHME
0.9 (0.73 - 1.08) 2011 Modelled IHME
0.9 (0.73 - 1.08) 2010 Modelled IHME
0.9 (0.74 - 1.09) 2009 Modelled IHME
0.9 (0.74 - 1.09) 2008 Modelled IHME
0.91 (0.74 - 1.10) 2007 Modelled IHME
0.91 (0.75 - 1.10) 2006 Modelled IHME
0.92 (0.75 - 1.11) 2005 Modelled IHME
0.92 (0.76 - 1.12) 2004 Modelled IHME
0.92 (0.76 - 1.13) 2003 Modelled IHME
0.93 (0.76 - 1.14) 2002 Modelled IHME
0.93 (0.77 - 1.15) 2001 Modelled IHME
0.94 (0.77 - 1.16) 2000 Modelled IHME
0.94 (0.77 - 1.16) 1999 Modelled IHME
0.95 (0.78 - 1.16) 1998 Modelled IHME
0.95 (0.78 - 1.16) 1997 Modelled IHME
0.95 (0.78 - 1.16) 1996 Modelled IHME
0.95 (0.78 - 1.16) 1995 Modelled IHME
0.95 (0.78 - 1.16) 1994 Modelled IHME
0.95 (0.77 - 1.15) 1993 Modelled IHME
0.94 (0.77 - 1.15) 1992 Modelled IHME
0.94 (0.76 - 1.14) 1991 Modelled IHME
0.93 (0.75 - 1.13) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.9 (0.60 - 1.50) 2011 Survey/reported Vilibic-Cavlek T et al, 2014
Men who have sex with men (MSM)
Download
Value (%) Year Type Source
2.9 (1.10 - 6.30) 2006 Survey/reported Cavlek TV etal , 2009
2.5 (1.10 - 4.70) 2006 Survey/reported Bozicevic I et al, 2009
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
36.7 (28.10 - 45.30) 2015 Modelled Degenhardt L et al, 2017
44 (37 - 51.20) 2007 Survey/reported EMCDDA
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
13.3 (12.50 - 14.20) 2016 Modelled ECDC

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
20 (14 - 27) 2019 Modelled IHME
20 (14 - 27) 2018 Modelled IHME
20 (14 - 27) 2017 Modelled IHME
20 (14 - 26) 2016 Modelled IHME
20 (13 - 26) 2015 Modelled IHME
20 (14 - 26) 2014 Modelled IHME
20 (14 - 26) 2013 Modelled IHME
19 (13 - 26) 2012 Modelled IHME
20 (13 - 26) 2011 Modelled IHME
20 (13 - 26) 2010 Modelled IHME
19 (13 - 26) 2009 Modelled IHME
19 (13 - 26) 2008 Modelled IHME
19 (13 - 26) 2007 Modelled IHME
19 (13 - 25) 2006 Modelled IHME
19 (12 - 25) 2005 Modelled IHME
19 (13 - 26) 2004 Modelled IHME
19 (13 - 25) 2003 Modelled IHME
19 (13 - 26) 2002 Modelled IHME
19 (13 - 26) 2001 Modelled IHME
19 (13 - 26) 2000 Modelled IHME
19 (13 - 26) 1999 Modelled IHME
20 (13 - 27) 1998 Modelled IHME
20 (13 - 27) 1997 Modelled IHME
20 (14 - 27) 1996 Modelled IHME
20 (14 - 28) 1995 Modelled IHME
20 (14 - 28) 1994 Modelled IHME
20 (14 - 28) 1993 Modelled IHME
20 (14 - 28) 1992 Modelled IHME
21 (14 - 28) 1991 Modelled IHME
21 (14 - 28) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 2017 Survey/reported EMCDDA, 2019
146 (112 - 179) 2016 Survey/reported Handanagic S et al, 2016
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
54 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
1.08 (%)
2019
(0.99 - 1.17(%))
IHME
HCV (RNA/cAg+)
0.92 (%)
2019
(0.75 - 1.13(%))
IHME

Survey/surveillance

HBV (HBsAg+)
0.8 (%)
2011
(0.4 - 1.2(%))
Vilibic-Cavlek T et al, 2014
HCV (anti-HCV)
0.9 (%)
2011
(0.6 - 1.5(%))
Vilibic-Cavlek T et al, 2014

Hepatitis related deaths (national)

Modelled

HBV
263
2019
(184 - 363)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
271
2019
(189 - 379)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.09 (%)
2019, latest modelled
(0.07 - 0.11(%))
IHME

Prevalence PWID

HCV
36.70 (%)
2015, latest modelled
(28.10 - 45.30(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
98 (%)
2014
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
192
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines